No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

2/3

Purple Biotech

Icahn School of Medicine

Tri-Specific

Antibody Platform

CAPTN-3 multi-specific

engagers

Oncology

Unspecified
(Immunoregulation of the

TME)

Preclinical

n/d

2

2/3

Vanda

Pharmaceuticals

Anaptys

Imsidolimab

IL-36R antagonist

Immunology

Generalized Pustular Psoriasis

Phase 3

50

3

2/4

Grifols

FcR Therapeutics

Recombinant nanobodies

Fc Receptor Inhibitor

Immunology

Autoimmune diseases

Discovery

n/d

4

2/4

Akos Biosciences

Restoration Biologics

n/d

Cannabinoid-COX-2

conjugate compounds

Immunology

Joint Disease
(Osteoarthritis, RA)

Discovery

n/d

5

2/4

Shionogi

Jordan’s Guardian Angels

Zatolmilast

PDE-AD inhibitor

Neurology

Jordan’s Syndrome,
Fragile X syndrome

Phase 2/3

n/d

6

2/10

Eli Lilly

AdvanCell

Pb-212 production technology

RPT; lead-212-labeled

radioligands

Oncology

Cancer

-

n/d

7

2/10

Eli Lilly

OliX Pharmaceuticals

OLX75016

MARC1 siRNA

Metabolic

Disorder

MASH

Phase 1

630

8

2/10

Flu Lab

ENA Respiratory

INNA-051

TLR2 agonist, TLR6 agonist

Infectious

Disease

H3N2 influenza virus infection

Phase 2

5

9

2/10

Hoth

Therapeutics

OnTargetx R&D Inc.

HT-KIT

c-Kit mRNA

Oncology

Mast cell-derived cancers
(ASM, SM-AHN, MCL),
Gastrointestinal cancer

Preclinical

n/d

10

2/10

PHC

 Corporation

Canadian Centre for

Commercialization of

Regenerative Medicine

LiCellGrowTM 외

Primary T-Cell Expansion

Culture Processes

Oncology

Cancer

-

n/d

11

2/12

AbbVie

Xilio Therapeutics

Masking TCE program

novel immunotherapies,

 including masked T-cell

engagers

Oncology

Solid tumor

Preclinical

2,100

12

2/12

Boehringer

Ingelheim

ExpressionEdits

Genetic Syntax Engine TM

AI-powered platform; uses

optimized introns to enhance gene expression

-

-

-

n/d

13

2/12

Breakthrough

T1D

Diamyd Medical AB

Diamyd

Autoimmune diabetes vaccine

Metabolic

Disorder

T1D

Phase 3

1.75

14

2/12

TG

Therapeutics

MaxCyte

ExPERT™

Electroporation technology
(to develop a CD19 CAR-T)

Immunology

MS

Phase 1

n/d

15

2/13

Tivic

health systems

Statera Biopharma

Entolimod

Entalasta

TLR5 agonist

TLR5 agonist

Hematology
Hematology

Acute radiation syndrome
Neutropenia, Poisoning

Preclinical
Discovery

n/d

16

2/13

Newleos

Therapeutics

ROCHE

NTX-1955
NTX-1472
Ralmitaront
Basmisanil

GABA A receptor γ-1 PAM

V1a antagonist

TAAR1 receptor agonist

TAAR1 receptor agonist

Neurology
Neurology
Neurology

Neurology

Anxiety
Anxiety
Substance use disorders

Substance use disorders

Phase 1
Phase 1
Phase 1

Phase 1

n/d

17

2/18

Cyrano

Therapeutics

KYORIN Pharmaceutical

CYR-064

PDE-1 antagonist

Infectious

Disease

Post-viral hyposmia

Phase 2

n/d

18

2/18

Biogen

Stoke Therapeutics

Zorevunersen

SCN1A(esp. Nav1.1) mRNA

Neurology

Dravet syndrome

Phase 2

550

19

2/19

Radiance

Biopharma

CSPC Megalith

Biopharmaceutical

RB-164(SYS-6005)

ROR1 ADC

Oncology

Hematologic malignancies,
NSCLC,
Ovartian cancer

IND
IND
IND

165

20

2/20

Incyte

Genesis Therapeutics

GEMS Platform

AI-powered platform;
to develop small molecule medicines against undisclosed targets

-

-

Discovery

885

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

2/6

Alumis

ACELYRIN

Lonigutamab

αIGF-1R antibody

Ophthalmology

Thyroid eye disease

Preclinical

n/d

2

2/11

Novartis

Anthos Therapeutics

Abelacimab

αFactor XI antibody

Cardiovascular

Thrombosis

Phase 3

3,100

3

2/18

Gate Neurosciences

Boost Neuroscience

Human synapse network analysis platform

Synapse-targeted drug discovery/development program

Neurology

Synaptopathies, CNS diseases

-

n/d

4

2/26

Renovaro

BioSymetrics

Elion platform

AI in vivo modeling and
 machine vision systems

Oncology,
Immunology

-

Discovery

n/d